The benefit of abemaciclib in prognostic subgroups: An update to the pooled analysis of MONARCH 2 and 3

被引：1
|
作者：
O'Shaughnessy, Joyce [1 ]
Goetz, Matthew P. [2 ]
Sledge, George W. [3 ]
Martin, Miguel [4 ,5 ]
Lin, Yong [6 ]
Forrester, Tammy [6 ]
Smith, Ian C. [6 ]
Di Leo, Angelo [7 ]
Johnston, Stephen [8 ]
机构：
[1] Baylor Univ, Med Ctr, Texas Oncol, US Oncol, Dallas, TX USA
[2] Mayo Clin, Rochester, MN USA
[3] Stanford Univ, Stanford, CA 94305 USA
[4] Geicam, Inst Invest Sanitaria Gregorio Maranon, Ciberonc, Madrid, Spain
[5] Univ Complutense, Madrid, Spain
[6] Eli Lilly & Co, Indianapolis, IN 46285 USA
[7] Hosp Prato, Prato, Italy
[8] Royal Marsden NHS Fdn Trust, London, England
来源：
CANCER RESEARCH | 2018年 / 78卷 / 13期
关键词：
D O I：
10.1158/1538-7445.AM2018-CT099
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
CT099
引用
收藏
页数：2
相关论文
共 50 条
  • [21] MONARCH 3: Abemaciclib as initial therapy for patients with HR+, HER2-advanced breast cancer - Results from the preplanned final PFS analysis
    Goetz, Matthew P.
    Martin, Miguel
    Di Leo, Angelo
    Im, Seock-Ah
    Awada, Ahmad
    Forrester, Tammy
    Frenzel, Martin
    Cox, Joanne
    Barriga, Susana
    Toi, Masakazu
    Iwata, Hiroji
    Johnston, Stephen
    CANCER RESEARCH, 2018, 78 (13)
  • [22] Clinical Significance of PIK3CA and ESR1 Mutations in Circulating Tumor DNA: Analysis from the MONARCH 2 Study of Abemaciclib plus Fulvestrant
    Tolaney, Sara M.
    Toi, Masakazu
    Neven, Patrick
    Sohn, Joohyuk
    Grischke, Eva-Maria
    Llombart-Cussac, Antonio
    Soliman, Hatem
    Wang, Hong
    Wijayawardana, Sameera
    Jansen, Valerie M.
    Litchfield, Lacey M.
    Sledge, George W., Jr.
    CLINICAL CANCER RESEARCH, 2022, 28 (08) : 1500 - 1506
  • [23] Abemaciclib in combination with endocrine therapy for East Asian patients with HR+, HER2-advanced breast cancer: MONARCH 2 & 3 trials
    Toi, Masakazu
    Inoue, Kenichi
    Masuda, Norikazu
    Iwata, Hiroji
    Sohn, Joohyuk
    Hae Park, In
    Im, Seock-Ah
    Chen, Shin-Cheh
    Enatsu, Sotaro
    Turner, P. Kellie
    Andre, Valerie A. M.
    Hardebeck, Molly C.
    Sakaguchi, Sachi
    Goetz, Matthew P.
    Sledge, George W., Jr.
    CANCER SCIENCE, 2021, 112 (06) : 2381 - 2392
  • [24] Final Overall Survival Analysis of Monarch 2: A Phase 3 trial of Abemaciclib Plus Fulvestrant in Patients with Hormone Receptor-Positive, HER2-Negative Advanced Breast Cancer
    Llombart-Cussac, Antonio
    Sledge, George
    Toi, Masakazu
    Neven, Patrick
    Sohn, Joo Hyuk
    Inoue, Kenichi
    Pivot, Xavier
    Okera, Meena
    Masuda, Norikazu
    Kaufman, Peter A.
    Koh, Han
    Grischke, Eva-Maria
    Conte, PierFranco
    Andre, Valerie
    Bian, Yuanyuan
    Shahir, Ashwin
    van Hal, Gertjan
    CANCER RESEARCH, 2023, 83 (05)
  • [25] Management of abemaciclib-associated adverse events in patients with HR+/HER2-advanced breast cancer: analysis of the MONARCH trials
    Rugo, H. S.
    Huober, J.
    Llombart-Cussac, A.
    Toi, M.
    Tolaney, S.
    Andre, V.
    Barriga, S.
    Forrester, T.
    Sledge, Jr G. W.
    Goetz, M. P.
    ONCOLOGY RESEARCH AND TREATMENT, 2019, 42 : 289 - 289
  • [26] Progression free survival (PFS) benefit from first line endocrine based therapies in postmenopausal women with HR+HER2-metastatic breast cancer (MBC) according to different prognostic subgroups: A combined analysis of data from PALOMA 2, MONALEESA 2, MONARCH 3, FALCON, SWOG and FACT trials
    Rossi, V.
    Giannarelli, D.
    Berchialla, P.
    Nistico, C.
    Ferretti, G.
    Gasparro, S.
    Malaguti, P.
    Russillo, M.
    Catania, G.
    Vigna, L.
    Mancusi, R. L.
    Cognetti, F.
    Fabi, A.
    ANNALS OF ONCOLOGY, 2018, 29 : 111 - 111
  • [27] Safety in Japanese Advanced Breast Cancer Patients Who Received Abemaciclib in MONARCH 2 and MONARCH 3: Assessment of Treatment-Emergent Neutropenia, Diarrhea, and Increased Alanine Aminotransferase and Aspartate Aminotransferase Levels
    Masuda, Norikazu
    Chen, Yucherng
    Kawaguchi, Tsutomu
    Dozono, Koji
    Toi, Masakazu
    CANCER MANAGEMENT AND RESEARCH, 2022, 14 : 1179 - 1194
  • [28] Assessment of the MONARCH-2-Study Results: G-BA confirms Additional Benefit of Abemaciclib in the Second-line Therapy of Patients with advanced HR +, HER2-Breast Cancer
    不详
    ONCOLOGY RESEARCH AND TREATMENT, 2020, 43 (10) : 566 - 566
  • [29] Consistent Inhibition of Joint Destruction By Denosumab in Important Subgroups of Japanese Patients with Rheumatoid Arthritis: Pooled Analysis of Phase 2 and 3 Studies
    Tanaka, Yoshiya
    Takeuchi, Tsutomu
    Soen, Satoshi
    Ishiguro, Naoki
    Yamanaka, Hisashi
    Yoneda, Toshiyuki
    Tanaka, Sakae
    Nitta, Takaya
    Okubo, Naoki
    Genant, Harry K.
    van der Heijde, Desiree
    ARTHRITIS & RHEUMATOLOGY, 2017, 69
  • [30] BENEFIT OF MULTIPLE INCOBOTULINUMTOXINA INJECTIONS FOR PAIN REDUCTION IN ADULT PATIENTS WITH LIMB SPASTICITY: POOLED ANALYSIS OF PHASE 2/3 STUDIES
    Wissel, J.
    Camoes-Barbosa, A.
    Comes, G.
    Althaus, M.
    Scheschonka, A.
    Simpson, D. M.
    PARKINSONISM & RELATED DISORDERS, 2023, 113 : 76 - 76
12345